ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.056
Day Range
$0.056 – $0.057
Volume
0.00
Avg Volume (10D)
162.80K
Market Cap
$20.65M
Price Chart
Market Statistics
Open$0.056
Previous Close$0.056
Day High$0.057
Day Low$0.056
Valuation
Market Cap20.65M
Shares Outstanding368.68M
Price to Book8.25
Trading Activity
Volume0.00
Value Traded0.00
Bid$0.056 × 22,722
Ask$0.059 × 102,725
Performance
1 Day0.00%
5 Day-13.85%
13 Week-32.53%
52 Week-6.67%
YTD-46.67%
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.